PRME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PRME is not a good buy right now for an impatient investor. The chart is only mildly bullish (price below the key pivot with weakening momentum), there are no near-term news catalysts, and Intellectia signals are absent today. While insider buying and bullish options positioning are positives, the near-term pattern stats lean slightly negative over the next week, making the current $3.99 level a “hold/avoid new entry” rather than a clean, high-conviction buy.
Price/levels: PRME is $3.99, below the pivot at 4.197, with nearby support at S1=3.827 and deeper support at S2=3.598; resistance levels are R1=4.568 and R2=4.797. Trend: moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has improved. Momentum: MACD histogram is positive (0.0104) but positively contracting, implying upside momentum is fading; RSI(6) ~50 is neutral. Short-horizon stats: pattern-based projection indicates a modest bearish bias near-term (40% chance of -0.55% next day and -1.35% next week) with a better 1-month outlook (+3.97%).
Intellectia Proprietary Trading Signals
Insider activity: insiders are buying, with the buying amount reportedly up ~18,302.86% over the last month (strong internal confidence signal).
Options sentiment: call-skewed positioning (low put/call ratios) supports a bullish bias among derivatives traders.
Analyst initiation: LifeSci Capital initiated with Outperform and a $6 target, highlighting “one-and-done” gene editing programs (Wilson’s disease, A1AT deficiency, cystic fibrosis) as long-term upside drivers.
No near-term news/catalysts: no news in the past week, reducing the probability of an immediate event-driven breakout.
Momentum not confirming: MACD is still positive but weakening; price is below the pivot (4.197), which commonly acts as a near-term trend gate.
Fundamental burn persists: the company remains deeply loss-making, which can cap upside in risk-off periods even when revenue spikes from partnerships/other sources.
Wall Street caution: multiple Neutral ratings and a recent price target cut (Citi) reflect a “wait for milestones” stance.
Latest quarter: 2025/Q3. Revenue increased to ~$1.225M (+486.12% YoY), but profitability deteriorated: net income was -$50.58M (down -3.69% YoY) and EPS was -$0.32 (down -27.27% YoY). Gross margin is shown as 100% (typical for early-stage/recognized revenue mix), but the key takeaway is that operating losses remain large despite revenue growth—this is still a milestone-driven, cash-burn profile.
Recent trend: sentiment is mixed-to-cautious. Citi (2025-11-11) kept Neutral and cut PT to $4.25 from $5 (downward revision). JPMorgan (2025-11-18) maintained Neutral and noted it would consider recommending shares closer to value-creating milestones (wait-and-see). LifeSci Capital (2025-12-23) initiated Outperform with a $6 PT (more optimistic long-term view). Wall Street pros: differentiated gene-editing platform and multiple high-unmet-need targets. Cons: reliance on clinical/regulatory milestones, ongoing large losses, and limited near-term catalysts. Political/congress activity: no recent congress trading data available; no politician/influential-figure trading information provided.
